# Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

> **NCT01805908** · PHASE1 · TERMINATED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 3 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** 111In-Pertuzumab + SPECT-CT

## Key facts

- **NCT ID:** NCT01805908
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Accrual is very poor
- **Last updated:** 2016-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01805908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01805908, "Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01805908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*